Unknown causative features in drug activity prediction
Identify currently unknown causative molecular features that determine small-molecule activity against their cognate targets and incorporate these features into the representations used by AI models to improve predictive performance.
References
A more concerning possibility is that some of the causative features are not modelled. This could happen because we do not know about them.
Yet the cliff error still sits well above the overall error, as it does for every method, indicating that the benchmark is not solved. Predicting the sharp, local changes in activity that define cliffs remains an open problem.
Other selections have no obvious chemical explanation. Liver-injury portfolios most often pick the same cardiotoxicity classifier (3 of 6 cells) and an electronic-spectra block (2 of 6), and blood--brain-barrier portfolios also select antimicrobial models (3 of 6). We do not know why these models help; the method makes such choices visible without guaranteeing a coherent chemical story.